Erasmus University Medical Center, Department of Internal Medicine and Department of Medical Microbiology and Infectious Diseases, Rotterdam, the Netherlands.
Astar Medical Center, Lviv, Ukraine.
Euro Surveill. 2022 Dec;27(48). doi: 10.2807/1560-7917.ES.2022.27.48.2200338.
BackgroundAdequate identification and testing of people at risk for HIV is fundamental for the HIV care continuum. A key strategy to improve timely testing is HIV indicator condition (IC) guided testing.AimTo evaluate the uptake of HIV testing recommendations in HIV IC-specific guidelines in European countries.MethodsBetween 2019 and 2021, European HIV experts reviewed guideline databases to identify all national guidelines of 62 HIV ICs. The proportion of HIV IC guidelines recommending HIV testing was reported, stratified by subgroup (HIV IC, country, eastern/western Europe, achievement of 90-90-90 goals and medical specialty).ResultsOf 30 invited European countries, 15 participated. A total of 791 HIV IC guidelines were identified: median 47 (IQR: 38-68) per country. Association with HIV was reported in 69% (545/791) of the guidelines, and 46% (366/791) recommended HIV testing, while 42% (101/242) of the AIDS-defining conditions recommended HIV testing. HIV testing recommendations were observed more frequently in guidelines in eastern (53%) than western (42%) European countries and in countries yet to achieve the 90-90-90 goals (52%) compared to those that had (38%). The medical specialties internal medicine, neurology/neurosurgery, ophthalmology, pulmonology and gynaecology/obstetrics had an HIV testing recommendation uptake below the 46% average. None of the 62 HIV ICs, countries or medical specialties had 100% accurate testing recommendation coverage in all their available HIV IC guidelines.ConclusionFewer than half the HIV IC guidelines recommended HIV testing. This signals an insufficient adoption of this recommendation in non-HIV specialty guidelines across Europe.
充分识别和检测艾滋病毒高危人群是实现艾滋病毒护理连续体的基础。改善及时检测的关键策略是艾滋病毒指标疾病(IC)指导检测。
评估欧洲国家艾滋病毒指标疾病特异性指南中艾滋病毒检测建议的采纳情况。
在 2019 年至 2021 年期间,欧洲艾滋病毒专家审查了指南数据库,以确定所有 62 种艾滋病毒指标疾病的国家指南。报告了按艾滋病毒指标疾病、国家、东欧/西欧、90-90-90 目标的实现情况和医学专业等亚组划分的艾滋病毒指标疾病指南推荐艾滋病毒检测的比例。
在受邀的 30 个欧洲国家中,有 15 个国家参与了研究。共确定了 791 项艾滋病毒指标疾病指南:每个国家的中位数为 47 项(IQR:38-68)。在指南中报告了与艾滋病毒的关联的占 69%(545/791),46%(366/791)建议进行艾滋病毒检测,而 42%(101/242)的艾滋病定义疾病建议进行艾滋病毒检测。在东部(53%)而非西部(42%)欧洲国家以及尚未实现 90-90-90 目标(52%)的国家,比已经实现目标(38%)的国家,艾滋病毒检测建议更频繁地出现在指南中。内科、神经病学/神经外科、眼科、肺病学和妇科/产科等医学专业的艾滋病毒检测建议采纳率低于 46%的平均水平。在所有可用的艾滋病毒指标疾病指南中,没有一个艾滋病毒指标疾病、国家或医学专业的检测建议涵盖率达到 100%。
不到一半的艾滋病毒指标疾病指南建议进行艾滋病毒检测。这表明在整个欧洲,非艾滋病毒专业指南中对这一建议的采纳不足。